Page 253 - Haematologica May 2020

Cardiac biomarkers in Mayo stage I amyloidosis
after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101(4):766-769.
7. Kastritis E, Papassotiriou I, Terpos E, et al. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. Blood. 2016;128(3):405-409.
8. Kastritis E, Papassotiriou I, Merlini G. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Blood. 2018;131(14):1568-1575.
9. Russo P, Palladini G, Foli A, et al. Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinc- tive clinical features and role of light chain type in 225 patients. Amyloid. 2011;18 Suppl 1:92-93.
10. Fontana M, Pica S, Reant P, et al. Prognostic value of late gadolinium enhancement car- diovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16): 1570-1579.
11. Lovat LB, Persey MR, Madhoo S, Pepys
MB, Hawkins PN. The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients. Gut. 1998;42(5):727-734.
12. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treat- ment response in immunoglobulin light chain amyloidosis (AL): a consensus opin- ion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79(4):319-328.
13. Wechalekar AD, Gillmore JD, Wassef N, Lachmann HJ, Whelan C, Hawkins PN. Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involve- ment at presentation is a risk factor for development of cardiac amyloidosis. Haematologica. 2011;96(7):1079-1080.
14. Dittrich T, Benner A, Kimmich C, et al. Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. Haematologica. 2019;
15. Wan K, Sun J, Han Y, et al. Increased prog-
nostic value of query amyloid late enhance- ment score in light-chain cardiac amyloido- sis. Circ J. 2018;82(3):739-746.
16. Gertz MA, Kyle RA. Hepatic amyloidosis: clinical appraisal in 77 patients. Hepatology. 1997;25(1):118-121.
17. Fradley MG, Larson MG, Cheng S, et al. Reference limits for N-terminal-pro-B-type natriuretic peptide in healthy individuals (from the Framingham Heart Study). Am J Cardiol. 2011;108(9):1341-1345.
18. Palladini G, Milani P, Foli A, et al. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood. 2018;131(5):525-532.
19. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107(19):2440-2445.
20. Kumar SK, Gertz MA, Lacy MQ, et al. Recent improvements in survival in pri- mary systemic amyloidosis and the impor- tance of an early mortality risk score. Mayo Clin Proc. 2011;86(1):12-18.
haematologica | 2020; 105(5)
1413